Fig. 2: PFS in patient subgroups. | Leukemia

Fig. 2: PFS in patient subgroups.

From: Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

Fig. 2

PFS, progression-free survival; D-Rd, daratumumab/lenalidomide/dexamethasone; Rd, lenalidomide/dexamethasone; CI, confidence interval; NE, not estimable; ISS, International Staging System; MM, multiple myeloma; Ig, immunoglobulin; ECOG, Eastern Cooperative Oncology Group; CrCl, creatinine clearance; PI, proteasome inhibitor; FISH, fluorescence in situ hybridization. aImpaired hepatic function included mild, moderate, and severe hepatic dysfunction as per National Cancer Institute organ dysfunction criteria. bCytogenetic risk was determined by FISH or karyotyping. cPatients with high cytogenetic risk had t(4;14), t(14;16), or del17p abnormalities.

Back to article page